Pascal Fender

Dr. Pascal Fender

CNRS - French National Center for Scientific Research
+2
orcid
Team Leader at IBS Grenoble

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2010 in Nature Medicine
Verified
Journal Article
Open access
PDF file
HWHongjie Wang
Hongjie Wang
ZLZong-Yi Li
Zong-Yi Li
YLYing Liu
Ying Liu
JPJonas Persson
Jonas Persson
IBInes Beyer
Ines Beyer
ALAndré Lieber
André Lieber
A subset of series B adenoviruses binds epithelial cells via a previously unknown receptor. Wang et al. now identify this receptor as desmoglein-2 (DSG-2), which has a role in intercellular adhesion. Binding of group B Ad3 to DSG-2 triggered an epithelial to mesenchymal transition, opened intercellular junctions and increased access to junction-localized proteins, which together may contribute to the spread of these viruses though epithelial tissues. We have identified desmoglein-2 (DSG-2) as the primary high-affinity receptor used by adenoviruses Ad3, Ad7, Ad11 and Ad14. These serotypes represent key human pathogens causing respiratory and urinary tract infections. In epithelial cells, adenovirus binding of DSG-2 triggers events reminiscent of epithelial-to-mesenchymal transition, leading to transient opening of intercellular junctions. This opening improves access to receptors, for example, CD46 and Her2/neu, that are trapped in intercellular junctions. In addition to complete virions, dodecahedral particles (PtDds), formed by excess amounts of viral capsid proteins, penton base and fiber during viral replication, can trigger DSG-2–mediated opening of intercellular junctions as shown by studies with recombinant Ad3 PtDds. Our findings shed light on adenovirus biology and pathogenesis and may have implications for cancer therapy.

1 January 1997 in Nature Biotechnology
Verified
Journal Article
Closed access
Pascal FenderPascal Fender
Pascal Fender
RRRob W.H. Ruigrok
Rob W.H. Ruigrok
EGEvelyne Gout
Evelyne Gout
SBSebastien Buffet
Sebastien Buffet
JCJadwiga Chroboczek
Jadwiga Chroboczek

1 July 2011 in Journal of Virology
Verified
Journal Article
Open access
PDF file
HWHongjie Wang
Hongjie Wang
ZLZongYi Li
ZongYi Li
RYRoma Yumul
Roma Yumul
SLStephanie Lara
Stephanie Lara
AHAkseli Hemminki
Akseli Hemminki
ALAndré Lieber
André Lieber
Recently, we identified desmoglein 2 (DSG2) as the main receptor for a group of species B adenoviruses (Ads), including Ad3, a serotype that is widely distributed in the human population (H. Wang et al., Nat. Med. 17: 96–104, 2011). In this study, we have attempted to delineate structural details of the Ad3 interaction with DSG2. For CAR- and CD46-interacting Ad serotypes, attachment to cells can be completely blocked by an excess of recombinant fiber knob protein, while soluble Ad3 fiber knob only inefficiently blocks Ad3 infection. We found that the DSG2-interacting domain(s) within Ad3 is formed by several fiber knob domains that have to be in the spatial constellation that is present in viral particles. Based on this finding, we generated a small recombinant, self-dimerizing protein containing the Ad3 fiber knob (Ad3-K/S/Kn). Ad3-K/S/Kn bound to DSG2 with high affinity and blocked Ad3 infection. We demonstrated by confocal immunofluorescence and transmission electron microscopy analyses that Ad3-K/S/Kn, through its binding to DSG2, triggered the transient opening of intercellular junctions in epithelial cells. The pretreatment of epithelial cells with Ad3-K/S/Kn resulted in increased access to receptors that are localized in or masked by epithelial junctions, e.g., CAR or Her2/ neu . Ad3-K/S/Kn treatment released CAR from tight junctions and thus increased the transduction of epithelial cells by a serotype Ad5-based vector. Furthermore, the pretreatment of Her2/ neu -positive breast cancer cells with Ad3-K/S/Kn increased the killing of cancer cells by the Her2/ neu -targeting monoclonal antibody trastuzumab (Herceptin). This study widens our understanding of how Ads achieve high avidity to their receptors and the infection of epithelial tissue. The small recombinant protein Ad3-K/S/Kn has practical implications for the therapy of epithelial cancer and gene/drug delivery to normal epithelial tissues.

13 November 2011 in Cancer Research
Verified
Journal Article
Closed access
PDF file
IBInes Beyer
Ines Beyer
RRRuan van Rensburg
Ruan van Rensburg
RSRobert Strauss
Robert Strauss
ZLZongYi Li
ZongYi Li
HWHongjie Wang
Hongjie Wang
ALAndré Lieber
André Lieber
The efficacy of monoclonal antibodies (mAb) used to treat solid tumors is limited by intercellular junctions which tightly link epithelial tumor cells to each another. In this study, we define a small, recombinant adenovirus serotype 3-derived protein, termed junction opener 1 (JO-1), which binds to the epithelial junction protein desmoglein 2 (DSG2). In mouse xenograft models employing Her2/neu- and EGFR-positive human cancer cell lines, JO-1 mediated cleavage of DSG2 dimers and activated intracellular signaling pathways which reduced E-cadherin expression in tight junctions. Notably, JO-1-triggered changes allowed for increased intratumoral penetration of the anti-Her2/neu mAb trastuzumab (Herceptin) and improved access to its target receptor, Her2/neu, which is partly trapped in tight junctions. This effect translated directly into increased therapeutic efficacy of trastuzumab in mouse xenograft models using breast, gastric, and ovarian cancer cells that were Her2/neu-positive. Furthermore, combining JO-1 with the EGFR-targeting mAb cetuximab (Erbitux) greatly improved therapeutic outcomes in a metastatic model of EGFR-positive lung cancer. A combination of JO-1 with an approach that triggered transient degradation of tumor stroma proteins elicited eradication of tumors. Taken together, our findings offer preclinical proof of concept to employ JO-1 in combination with mAb therapy. Cancer Res; 71(22); 7080–90. ©2011 AACR.

1 June 2012 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
HWHongjie Wang
Hongjie Wang
IBInes Beyer
Ines Beyer
JPJonas Persson
Jonas Persson
HSHui Song
Hui Song
ZLZongYi Li
ZongYi Li
ALAndré Lieber
André Lieber
We have recently reported that a group of human adenoviruses (HAdVs) uses desmoglein 2 (DSG2) as a receptor for infection. Among these are the widely distributed serotypes HAdV-B3 and HAdV-B7, as well as a newly emerged strain derived from HAdV-B14. These serotypes do not infect rodent cells and could not up until now be studied in small-animal models. We therefore generated transgenic mice containing the human DSG2 locus. These mice expressed human DSG2 (hDSG2) at a level and in a pattern similar to those found for humans and nonhuman primates. As an initial application of hDSG2-transgenic mice, we used a green fluorescent protein (GFP)-expressing HAdV-B3 vector (Ad3-GFP) and studied GFP transgene expression by quantitative reverse transcription-PCR (qRT-PCR) and immunohistochemistry subsequent to intranasal and intravenous virus application. After intranasal application, we found efficient transduction of bronchial and alveolar epithelial cells in hDSG2-transgenic mice. Intravenous Ad3-GFP injection into hDSG2-transgenic mice resulted in hDSG2-dependent transduction of epithelial cells in the intestinal and colon mucosa. Our findings give an explanation for clinical symptoms associated with infection by DSG2-interacting HAdVs and provide a rationale for using Ad3-derived vectors in gene therapy.

1 February 2006 in Journal of Molecular Biology
Verified
Journal Article
Closed access
PFP. Fuschiotti
P. Fuschiotti
GSGuy Schoehn
Guy Schoehn
Pascal FenderPascal Fender
Pascal Fender
CFC.M.S. Fabry
C.M.S. Fabry
EHE.A. Hewat
E.A. Hewat
JCJames Conway
James Conway